Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $568.00

Praxis Precision Medicines (NASDAQ:PRAX – Free Report) had its price target hoisted by Robert W. Baird from $514.00 to $568.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has an outperform rating on the stock.

Several other brokerages also recently commented on PRAX. Wall Street Zen downgraded Praxis Precision Medicines from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Wedbush lifted their target price on Praxis Precision Medicines from $188.00 to $189.00 and gave the company an “underperform” rating in a research report on Tuesday, November 10th. Wells Fargo & Company cut their target price on Praxis Precision Medicines from $362.00 to $343.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 10th. UBS Group initiated coverage on Praxis Precision Medicines in a report on Wednesday, October 14th. They set a “buy” rating and a $706.00 price target for the company. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $945.00 price target on shares of Praxis Precision Medicines in a report on Monday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Praxis Precision Medicines currently has an average rating of “Moderate Buy” and a consensus target price of $656.42.

Read Our Latest Report on PRAX

Praxis Precision Medicines Stock Performance

Shares of NASDAQ PRAX opened at $305.19 on Monday. Praxis Precision Medicines has a fifty-two week low of $160.11 and a fifty-two week high of $392.70. The stock has a market cap of $8.53 billion, a price-to-earnings ratio of -23.84 and a beta of 2.85. The firm’s 50-day simple moving average is $287.32 and its 200 day simple moving average is $314.29.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($3.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.54) by $0.31. On average, sell-side analysts predict that Praxis Precision Medicines will post -13.72 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its position in Praxis Precision Medicines by 6.8% in the 1st quarter. Janus Henderson Group PLC now owns 3,458,863 shares of the company’s stock worth $1,113,514,000 after purchasing an additional 218,777 shares in the last quarter. Perceptive Advisors LLC increased its stake in Praxis Precision Medicines by 2.0% in the 1st quarter. Perceptive Advisors LLC now owns 2,035,986 shares of the company’s stock valued at $655,974,000 after buying an additional 40,000 shares during the last quarter. Bank of America Corp DE increased its stake in Praxis Precision Medicines by 2.3% in the 1st quarter. Bank of America Corp DE now owns 534,604 shares of the company’s stock valued at $172,244,000 after buying an additional 11,841 shares during the last quarter. Vivo Capital LLC increased its stake in Praxis Precision Medicines by 3.0% in the 1st quarter. Vivo Capital LLC now owns 338,895 shares of the company’s stock valued at $109,189,000 after buying an additional 10,000 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in Praxis Precision Medicines by 61.7% in the 3rd quarter. Marshall Wace LLP now owns 221,602 shares of the company’s stock valued at $64,537,000 after buying an additional 84,594 shares during the last quarter. 67.84% of the stock is currently owned by hedge funds and other institutional investors.

About Praxis Precision Medicines

(Get Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.

Further Reading

Analyst Recommendations for Praxis Precision Medicines (NASDAQ:PRAX)

Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.